v3.26.1
SCHEDULE OF SELECTED INFORMATION FOR REPORTABLE SEGMENTS (Details) - USD ($)
3 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]    
Operating income by Segment $ 11,475,074 $ 25,551,006
Abbreviated New Drug Applications [Member]    
Segment Reporting [Line Items]    
Operating income by Segment $ 11,475,074 $ 25,551,006